切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2019, Vol. 13 ›› Issue (05) : 354 -358. doi: 10.3877/cma.j.issn.1674-0793.2019.05.005

所属专题: 文献

论著

结直肠癌中F框蛋白2的表达与Ki-67、血管内皮生长因子及预后的关系
韦新颖1, 王霄1, 卜巨源1, 莫湘琼1, 侯冰宗1,()   
  1. 1. 519000 珠海,中山大学附属第五医院胃肠外科
  • 收稿日期:2018-08-05 出版日期:2019-10-01
  • 通信作者: 侯冰宗
  • 基金资助:
    广东省珠海市科技计划项目(20171009E030027)

Role of F-box protein 2, Ki-67 and vascular endothelial growth factor in the prognosis of colorectal cancer

Xinying Wei1, Xiao Wang1, Juyuan Bu1, Xiangqiong Mo1, Bingzong Hou1,()   

  1. 1. Department of Gastrointestinal Surgery, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China
  • Received:2018-08-05 Published:2019-10-01
  • Corresponding author: Bingzong Hou
  • About author:
    Corresponding author: Hou Bingzong, Email:
引用本文:

韦新颖, 王霄, 卜巨源, 莫湘琼, 侯冰宗. 结直肠癌中F框蛋白2的表达与Ki-67、血管内皮生长因子及预后的关系[J/OL]. 中华普通外科学文献(电子版), 2019, 13(05): 354-358.

Xinying Wei, Xiao Wang, Juyuan Bu, Xiangqiong Mo, Bingzong Hou. Role of F-box protein 2, Ki-67 and vascular endothelial growth factor in the prognosis of colorectal cancer[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2019, 13(05): 354-358.

目的

探讨结直肠癌中F-box蛋白家族成员F框蛋白2(FBXO2)的表达与肿瘤增殖指标(Ki-67)、血管内皮生长因子(VEGF)的表达及预后的关系。

方法

采用免疫组织化学MaxVision两步法检测105例结直肠癌组织标本中FBXO2、Ki-67及VEGF的表达情况,统计分析其与临床病理特征及预后的相关性。

结果

Ki-67、VEGF和FBXO2阳性表达率分别为53.3%(56/105)、51.4%(54/105)、44.7%(47/105)。Ki-67与结直肠癌的原发灶大小密切相关(P=0.017),VEGF与结直肠癌临床病理特征无明显相关性,FBXO2与结直肠癌患者的远处转移、AJCC临床分期密切相关(P=0.045、0.027)。Pearson相关分析提示,FBXO2与Ki-67、VEGF的表达呈显著相关(r=0.305、0.223,P=0.002、0.022),Ki-67与VEGF的表达无相关性(r=0.160,P=0.102)。多因素Cox比例危险模型分析提示,高表达的FBXO2是结直肠癌患者不良预后的独立影响因素(HR=2.183,95%CI=1.075~4.434,P=0.031)。生存分析显示,结直肠癌组织中Ki-67、VEGF及FBXO2高表达的患者生存时间明显低于低表达者,差异有统计学意义(P=0.019、0.036、<0.001)。

结论

FBXO2在结直肠癌的发生、发展中起到促癌的作用,是结直肠癌不良预后的独立影响因素,可能机制是通过泛素蛋白酶体途径参与调节结直肠癌的肿瘤增殖活性及新生血管形成。

Objective

To investigate the expression of FBXO2, Ki-67 and vascular endothelial growth factor (VEGF) in colorectal cancer (CRC), and their roles in the prognosis of CRC.

Methods

The expression levels of Ki-67, VEGF and FBXO2 were detected in one hundred and five pairs of primary CRC tissues by using immunohistochemistry (IHC), and their correlations with clinicopathological factors were statistically analyzed.

Results

The positive rates of Ki-67, VEGF and FBXO2 expression in CRC tissue samples were 53.3% (56/105), 51.4% (54/105), 44.7% (47/105), respectively. The high expression levels of Ki-67 was significantly correlated with tumor size (P=0.017). The high expression level of FBXO2 was significantly correlated with tumor metastasis (P=0.045) and AJCC stage (P=0.027). Pearson’s correlation analysis revealed significant correlation between FBXO2, Ki-67 and VEGF expression (r=0.305, 0.223, P=0.002, 0.022), while Ki-67 displayed no correlation with VEGF (r=0.160, P=0.102). Cox regression analysis revealed that FBXO2 was an independent prognostic factor for CRC patients (HR=2.183, 95%CI=1.075-4.434, P=0.031). Survival analysis showed that the survival time of patients with high expression of Ki-67, VEGF and FBXO2 in CRC tissue was significantly lower than those with low expression (P=0.019, 0.036, <0.001).

Conclusion

The high expression level of FBXO2 is associated with the proliferative rate of tumor cells and angiogenesis of CRC.

表1 FBXO2、Ki-67及VEGF表达与105例结直肠癌患者临床病理特征的关系(例)
图1 结直肠癌中FBXO2、Ki-67和VEGF的表达(MaxVision两步法×200) A为FBXO2,B为Ki-67,C为VEGF
表2 影响结直肠癌患者预后的多因素分析
图2 结直肠癌组织中FBXO2、Ki-67、VEGF不同表达水平的患者生存曲线比较 A为FBXO2,B为Ki-67,C为VEGF
[1]
Thompson SJ, Loftus LT, Ashley MD, et al. Ubiquitin-proteasome system as a modulator of cell fate[J]. Curr Opin Pharmacol, 2008, 8(1): 90-95.
[2]
Uddin S, Bhat AA, Krishnankutty R, et al. Involvement of F-BOX proteins in progression and development of human malignancies[J]. Semin Cancer Biol, 2016, 36: 18-32.
[3]
Nishio K, Yoshida Y, Tanaka K, et al. Structural analysis of a function-associated loop mutant of the substrate-recognition domain of Fbs1 ubiquitin ligase[J]. Acta Crystallogr F Struct Biol Commun, 2016, 72(Pt 8): 619-626.
[4]
Sun X, Wang T, Guan ZR, et al. FBXO2, a novel marker for metastasis in human gastric cancer[J]. Biochem Biophys Res Commun, 2018, 495(3): 2158-2164.
[5]
Kattan MW, Hess KR, Amin MB, et al. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine[J]. CA Cancer J Clin, 2016, 66(5): 370-374.
[6]
Atkin G, Hunt J, Minakawa E, et al. F-box only protein 2 (Fbxo2) regulates amyloid precursor protein levels and processing[J]. J Biol Chem, 2014, 289(10): 7038-7048.
[7]
Nelson RF, Glenn KA, Miller VM, et al. A novel route for F-box protein-mediated ubiquitination links CHIP to glycoprotein quality control[J]. J Biol Chem, 2006, 281(29): 20242-20251.
[8]
Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown[J]. J Cell Physiol, 2000, 182(3): 311-322.
[9]
Inwald EC, Klinkhammer-Schalke M, Hofstädter F, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry[J]. Breast Cancer Res Treat, 2013, 139(2): 539-552.
[10]
Li LT, Jiang G, Chen Q, et al. Ki67 is a promising molecular target in the diagnosis of cancer (review)[J]. Mol Med Rep, 2015, 11(3): 1566-1572.
[11]
Mohamed SY, Mohammed HL, Ibrahim HM, et al. Role of VEGF, CD105, and CD31 in the prognosis of colorectal cancer cases[J]. J Gastrointest Cancer, 2017.[Epub ahead of print]
[12]
Zhang Z, Zhang G, Gao Z, et al. Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer[J]. BMC Cancer, 2017, 17(1): 861.
[13]
Sun C, Tao Y, Gao Y, et al. F-box protein 11 promotes the growth and metastasis of gastric cancer via PI3K/AKT pathway-mediated EMT[J]. Biomed Pharmacother, 2018, 98: 416-423.
[14]
Nakopoulou L, Stefanaki K, Panayotopoulou E, et al. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation[J]. Hum Pathol, 2002, 33(9): 863-870.
[1] 罗青杉, 梅海涛, 郝家领, 蔡锦锋, 周润楷, 温玉刚. 连接蛋白43通过调控细胞周期抑制结直肠癌的增殖机制研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 344-349.
[2] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[3] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[4] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[5] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[6] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[7] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[8] 张蔚林, 王哲学, 白峻阁, 黄忠诚, 肖志刚. 利用TCGA数据库构建基于miRNA的结直肠癌列线图预后模型[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 381-388.
[9] 张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
[10] 任佳琪, 刁德昌, 何自衍, 张雪阳, 唐新, 李文娟, 李洪明, 卢新泉, 易小江. 网膜融合线导向的脾曲游离技术在左半结肠癌根治术中的应用[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 362-367.
[11] 张迪, 王春霞, 张学东, 李发馨, 庞淅文, 陈一锋, 张维胜, 王涛. 梗阻性左半结直肠癌自膨式金属支架置入后行腹腔镜手术与开腹手术的短期临床疗效比较[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 375-380.
[12] 季鹏程, 鄂一民, 陆晨, 喻春钊. 循环外泌体相关生物标志物在结直肠癌诊断中的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 265-273.
[13] 李佳莹, 王旭丹, 梁雪, 张雷, 李佳英. 1990~2021年中国结直肠癌死亡趋势分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 274-279.
[14] 戈伟, 陈刚. 纳米炭导航行淋巴示踪在结直肠癌TNM分期中淋巴分期价值的临床研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 288-293.
[15] 崔精, 鲍一帆, 沈晓明, 杨增辉, 高森, 鲍传庆. 结直肠癌中circMFSD12对肿瘤细胞功能及5-FU敏感性的调控[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 294-302.
阅读次数
全文


摘要